Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanruprubart in Guillain-Barré Syndrome
NCT07020819Phase 3Recruiting
- Sponsor
- Annexon Biosciences
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of tanruprubart in Guillain-Barré syndrome (GBS), sponsored by Annexon Biosciences. Primary endpoints: Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample at Day 15 and Observed Time to Maximum Observed Serum Concentration at Day 15. Started Sep 2025; status: recruiting.
02
Drugs
tanruprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT07020819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020819.